Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Show Submenu For Accessing medicines
Access to medicines in Wales
Medicine recommendations
Make a submission
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Who we are
What we do
Our committees
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
TA918: Bimekizumab for treating axial spondyloarthritis
TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA718: Ixekizumab for treating axial spondyloarthritis
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
10/08/2020
TA290: Mirabegron for treating symptoms of overactive bladder
10/08/2020
TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
05/08/2020
TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
05/08/2020
TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
05/08/2020
TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
05/08/2020
TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
05/08/2020
TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (replaced TA296)
05/08/2020
TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
05/08/2020
TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
05/08/2020
TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
05/08/2020
TA509:Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
05/08/2020
TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
05/08/2020
TA297: Ocriplasmin for treating vitreomacular traction
29/07/2020
TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
29/07/2020
TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
29/07/2020
TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
29/07/2020
TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
29/07/2020
TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
29/07/2020
TA401: Bosutinib for previously treated chronic myeloid leukaemia (replaced TA299)
29/07/2020
TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
2
3
4
5
6
7
8
9
10
11
12
Follow AWTTC: